264 related articles for article (PubMed ID: 32208488)
1. Interferon-complement loop in transplant-associated thrombotic microangiopathy.
Jodele S; Medvedovic M; Luebbering N; Chen J; Dandoy CE; Laskin BL; Davies SM
Blood Adv; 2020 Mar; 4(6):1166-1177. PubMed ID: 32208488
[TBL] [Abstract][Full Text] [Related]
2. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
3. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
4. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
6. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
7. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
Lazana I
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
[TBL] [Abstract][Full Text] [Related]
8. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
9. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
Sartain S; Shubert S; Wu MF; Wang T; Martinez C
Pediatr Blood Cancer; 2020 Mar; 67(3):e28070. PubMed ID: 31774252
[TBL] [Abstract][Full Text] [Related]
10. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
11. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
13. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
14. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.
Jodele S; Sabulski A
Expert Rev Hematol; 2021 Aug; 14(8):751-763. PubMed ID: 34301169
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Nrf2 Attenuates Oxidative Stress-Induced, Complement Activation-Associated Endothelial Injury and Apoptosis in Transplant-Associated Thrombotic Microangiopathy.
Zhang R; Qi J; Zhou M; Pan T; Zhang Z; Yao Y; Han H; Han Y
Transplant Cell Ther; 2021 Sep; 27(9):758.e1-758.e8. PubMed ID: 34174470
[TBL] [Abstract][Full Text] [Related]
17. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
Jodele S; Laskin BL; Dandoy CE; Myers KC; El-Bietar J; Davies SM; Goebel J; Dixon BP
Blood Rev; 2015 May; 29(3):191-204. PubMed ID: 25483393
[TBL] [Abstract][Full Text] [Related]
18. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Jodele S; Licht C; Goebel J; Dixon BP; Zhang K; Sivakumaran TA; Davies SM; Pluthero FG; Lu L; Laskin BL
Blood; 2013 Sep; 122(12):2003-7. PubMed ID: 23814021
[TBL] [Abstract][Full Text] [Related]
19. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy.
Okamura H; Nakamae H; Shindo T; Ohtani K; Hidaka Y; Ohtsuka Y; Makuuchi Y; Kuno M; Takakuwa T; Harada N; Nishimoto M; Nakashima Y; Koh H; Hirose A; Nakamae M; Wakamiya N; Hino M; Inoue N
Front Immunol; 2021; 12():695037. PubMed ID: 34326846
[TBL] [Abstract][Full Text] [Related]
20. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Dandoy CE; Myers KC; El-Bietar J; Nelson A; Wallace G; Laskin BL
Transfus Apher Sci; 2016 Apr; 54(2):181-90. PubMed ID: 27156964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]